918博天娱乐·(中国)官方网站

[News] Hua Medicine to Present Research Findings at CDS 2023

Hua Medicine
Nov 23, 2023
3963

November 20, 2023, Shanghai, China

Hua Medicine (HK:2552) today announced that it will present multiple research findings at the 25th Scientific Meeting of the Chinese Diabetes Society (CDS 2023).

Hua Medicine, along with its wholly owned subsidiary Nanjing AscendRare Pharmaceutical Technology Co., Ltd., will deliver a series of oral presentations and present posters to disseminate their latest research findings. The findings highlight Hua Medicine’s constant efforts to deepen and expand its research of glucokinase. Hua Medicine is also improving its capabilities in all stages of the innovative drug development process, from target identification to lead compound confirmation, in order to broaden its exploration of more disease areas and new drug R&D pipelines.

The Chinese Medical Association (CMA) and Chinese Diabetes Society (CDS) are hosting the 25th Scientific Meeting of the CDS, which is being organized by the Hubei Provincial Medical Association. The conference's goals are to raise the standard of diabetes research, diagnosis, and treatment in our nation and support the development of a healthy China. The conference will take place in Wuhan, Hubei province, from November 22 to 25.

The CDS is a professional society directly under the CMA. Since 2006, it has been the venue for an annual scientific conference that attracts diabetes professionals and businesses. It has grown to become the nation's preeminent and largest scientific conference for professionals in the field of diabetes.

Schedule

Oral presentation: Diabetes Drug R&D and Drug Mechanism Research

Time:

November 24, 16:17-16:25

Venue:

Chuxiu Room 107

Title:

Dorzagliatin, a glucokinase activator, repairs defective islet function in high-fat diet-induced diabetic mice

Main content:

The objective of this study is to assess the long-term efficacy of dorzagliatin in restoring islet function in a mouse model of diabetes. Even with a high-fat diet, islet function can recover over time, even after drug administration is discontinued. This occurrence gives biological support for additional clinical study into diabetes remission.

Speaker:

Nanjing AscendRare Pharmaceutical Technology Co., Ltd Dongnan Han

Oral Presentation: Islet Biology and Insulin Resistance

Time:

November 24, 16:57-17:05

Venue:

Chuhe Room 111

Title:

Drug development for disease caused by glutamate dehydrogenase (GDH) gain-of-function mutations

Main content:

Using an in-house new drug screening technology platform, which included virtual drug screening, activity verification of compounds on mutant proteins, and drug efficacy verification of disease models, multiple GDH inhibitors were discovered, providing new options for the treatment of rare diseases caused by GDH gain-of-function mutations.

Speaker:

Nanjing AscendRare Pharmaceutical Technology Co., Ltd, Yue Yuan

Oral Presentation: Diabetes Related Endocrine Diseases 1

Time:

November 24, 14:24-14:32

Venue:

Chuyue Room 109

Title:

Mechanisms of GDH gain-of-function mutation-induced hyperammonemia based on knock-in mouse model studies

Main content:

In addition to the occurrence of hypoglycemia, individuals with rare disorders resulting from gain-of-function mutations in the GDH gene also exhibit hyperammonemia, the underlying causes of which remain unknown. The investigation of a mouse model with a knock-in of mutant GDH gene has revealed insights into the effects of GDH mutations on amino acid metabolism and the underlying mechanism of hyperammonemia.

Speaker:

Beijing Children's Hospital, Capital Medical University, Chang Su


Poster code: 5548

Title:

Investigation into the molecular mechanisms that underlie the effects of dorzagliatin in GK rats to delay hyperglycemia and cognitive impairment.

Partners:

Hua Medicine (Shanghai) Ltd.
The Interdisciplinary Research Center on Biology and Chemistry

Main content:

Cognitive impairment in GK rats may be caused by aberrant expression of synaptic proteins in neurons as a result of insulin resistance and inadequate glucose uptake in nerve cells. This study discovered that by controlling brain glucose homeostasis, brain glucose uptake, and insulin resistance, continuous low-dose dorzagliatin treatment to GK rats from infancy can prevent GK rats from developing cognitive impairment phenotypes.

Poster code: 6246

Title:

Enzymological and islet function comparison between MK-0941 and GKA dorzagliatin

Partners:

Nanjing AscendRare Pharmaceutical Technology Co., Ltd.
Hua Medicine (Shanghai) Ltd.

Main content:

The findings of the study indicate that dorzagliatin demonstrates notable glucose concentration-dependent properties in its ability to stimulate glucokinase (GK) activity. The observed phenomena indicate that the impact is limited when the glucose concentration is low, but becomes more significant as the concentration of glucose increases. The infrequent incidence of hypoglycemia documented in clinical studies of dorzagliatin can be attributed to its underlying mechanism of action.

Poster code: 6839

Title:

Investigating the impact of glycine on glucose homeostasis and insulin secretion in mouse models and human subjects

Partners:

Nanjing AscendRare Pharmaceutical Technology Co., Ltd
Peking University First Hospital

Main content:

Clinical observations have indicated that the administration of oral glycine has the potential to enhance basal insulin secretion and increase glucose tolerance. However, the precise mechanism remains uncertain. This investigation employed islet perfusion tests and utilized mice with various disease models to elucidate the capacity of glycine to augment insulin secretion under distinct circumstances. The mechanism pertains to the manifestation of proteins peculiar to the central nervous system within pancreatic islets, including NMDA receptors. This finding presents an innovative pathway for further exploring the correlation between the functionality of pancreatic islets and the central nervous system.

Poster code: 4799

Title:

Application of oral mini-model to evaluate the improvement effect of dorzagliatin on islet function

Partners:

Peking University Third Hospital
Hua Medicine (Shanghai) Ltd.

Main content:

This research utilizes an oral mini-model approach to quantify the beneficial impact of dorzagliatin on patients diagnosed with type 2 diabetes. Research has shown that dorzagliatin significantly enhances the function of pancreatic islet in individuals with type 2 diabetes in comparison to a placebo. The ability of GKA to increase insulin secretion in response to glucose is consistent with enhanced beta-cell function.

Poster code: 6738

Title:

Investigation of a TIR prediction model based on glucose tolerance test and machine learning algorithm

Partners:

Nanjing First Hospital
Hua Medicine (Shanghai) Ltd.

Main content:

Continuous glucose monitoring (CGM) with plasma glucose time in range (TIR), one of the most important parameters for assessing blood glucose fluctuations, has been shown to be strongly associated with a variety of diabetes complications and is therefore recommended as a foundational standard for diabetes management alongside glycated hemoglobin (HbA1c). The objective of this research endeavor is to examine the correlation between fasting plasma glucose (FPG) and 2-hour postprandial plasma glucose (PPG), as measured by CGM parameters and the glucose tolerance test. Additionally, this study investigates the potential application of machine learning algorithms in developing a more precise target glycemic response (TIR) prediction model by utilizing HbA1c, FPG, and PPG. The outcomes of the TIR prediction model demonstrate that the multivariate nonlinear random forest model outperforms the TIR, thereby illuminating the abundance of plasma glucose fluctuation indicators embodied by the TIR and offering a novel perspective on the application of machine learning algorithms in diabetes management and more precise TIR prediction.


About Hua Medicine
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong, China. Hua Medicine is focused on developing novel therapies for patients around the world with unmet medical needs. Based on global resources, Hua Medicine teams up with high-caliber people to develop breakthrough technologies and products, which contribute to global innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets) targets the glucose sensor glucokinase, restores glucose sensitivity in Type 2 diabetes (T2D) patients and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin in metformin hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used by patients with T2D with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine has partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (华堂宁®) in China, benefiting diabetes patients and their families.

About AscendRare
Nanjing AscendRare Pharmaceutical Technology Co., Ltd is a wholly owned subsidiary of Hua Medicine, situated within the Nanjing Biotech and Pharmaceutical Valley in the Jiangbei New District. The company's primary focus lies in conducting research and development (R&D) activities pertaining to pharmaceuticals, specifically targeting the treatment of rare metabolic diseases. The overarching goal is to develop and deliver efficacious therapeutic interventions for rare metabolic diseases, with a particular emphasis on newborn hypoglycemia. Additionally, the company offers supplementary diagnostic services for rare diseases, encompassing functional investigations of mutant genes. The company has implemented an extensive pre-clinical research and development (R&D) technology platform. This platform encompasses various components such as computer-aided drug screening, compound optimization and synthesis, target protein function testing, compound screening, drug screening based on islet function, and drug efficacy determination using disease animal models. The company has also established R&D pipelines targeting different objectives. The company has been designated as a "Private Technology Enterprise," a "Small and Medium-sized Technology Enterprise," and a "Innovative Small and Medium-sized Enterprise." It has collaborated with numerous domestic and international universities and scientific research institutes to consistently broaden the investigation of illness mechanisms alongside the development of groundbreaking pharmaceuticals.

For more information
Hua Medicine
Website:  www.ksxianqing.com

Investors
E-mail: ir@ksxianqing.com

Media
E-mail: pr@ksxianqing.com

Focus Us
Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x
友情链接: